文献速递胸部肿瘤

晚期非小细胞肺癌靶向或免疫治疗中缓解深度与生存的探索性分析

Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy.
PubMed 文献 · Ann Oncol · 2017-01-01

该研究汇总了ALK抑制剂和抗PD-1抗体的随机对照试验实验组,按最大肿瘤缩小百分比将缓解深度分为Q0-Q4组,采用Cox模型分析缓解深度与PFS和OS的关联。结果显示,在ALK抑制剂和抗PD-1抗体治疗患者中,更大的缓解深度与更长的PFS和OS相关。

要点

  • 在ALK抑制剂治疗患者中,缓解深度越高,PFS和OS的HR越低。
  • 在抗PD-1抗体治疗患者中,缓解深度越高,PFS和OS的HR越低。
  • 缓解深度可能为临床试验提供额外的结局指标。

核心结论

  • 分析提示,在接受ALK抑制剂或抗PD-1抗体治疗的患者中,更大的缓解深度与更长的PFS和OS相关。

研究设计与样本

  • 回顾性探索性 responder 分析,汇总了ALK抑制剂的两项随机对照试验和抗PD-1抗体的两项随机对照试验的实验组。

主要发现

  • ALK抑制剂汇总分析中,Q0-Q4组分别有12、39、70、144、40例患者;缓解深度 vs PFS/OS的HR分别为Q1 0.19/0.94、Q2 0.11/0.56、Q3 0.05/0.28、Q4 0.03/0.05。
  • 抗PD-1抗体试验中,Q0-Q4组分别有168、70、44、45、28例患者;缓解深度 vs PFS/OS的HR分别为Q1 0.3/0.52、Q2 0.22/0.47、Q3 0.09/0.07、Q4 0.07/0.14。

关键数值与推荐

  • 缓解深度按最大肿瘤缩小百分比分为四分位:Q1=1%-25%,Q2=26%-50%,Q3=51%-75%,Q4=76%-100%,Q0为无缩小。

临床怎么用

  • 缓解深度可能为临床试验提供额外的结局指标,并可能有助于更好地比较治疗活性。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Response Evaluation Criteria in Solid Tumors (RECIST) permits rapid evaluation of new therapeutic strategies in cancer. However, RECIST does not capture the heterogeneity of response in highly active therapies. Depth of tumor response may provide a more granular view of response. We explored the association between, depth of response (DepOR), with overall survival (OS) and progression-free survival (PFS) for patients with NSCLC being treated with an ALK inhibitor (ALKi) or an anti-PD-1 antibody (Ab). METHODS: Experimental arms from two randomized controlled trials (RCTs) of an ALKi and two RCTs of an anti-PD-1 Ab were separately pooled. Patient responses were grouped into DepOR 'quartiles' by percentage of maximal tumor shrinkage (Q1 = 1%-25%, Q2 = 26%-50%, Q3 = 51%-75%, and Q4 = 76%-100%), Q0 had no shrinkage. We carried out a retrospective exploratory responder analysis to evaluate the association between DepOR and OS or PFS using hazard ratios (HR) generated by the Cox proportional hazards model. RESULTS: In the pooled ALK analysis there were 12, 39, 70, 144, and 40 patients in quartiles 0-4, respectively. The DepOR versus PFS/OS analyses HR were: 0.19/0.94 for Q1 0.11/0.56 for Q2, 0.05/0.28 for Q3, and 0.03/0.05 for Q4. In the PD-1 trials within quartiles 0-4 there were 168, 70, 44, 45, and 28 patients, respectively. The DepOR versus PFS/OS analyses HR were 0.3/0.52 for Q1, 0.22/0.47 for Q2, 0.09/0.07 for Q3, and 0.07/0.14 for Q4. CONCLUSIONS: Our analysis suggests a greater DepOR is associated with longer PFS and OS for patients receiving ALKi or anti-PD1 Ab. Overall, this suggests that DepOR may provide an additional outcome measure for clinical trials, and may allow better comparisons of treatment activity.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. McCoach CE, Blumenthal GM, Zhang L, et al. Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy. Ann Oncol. 2017. PMID: 29045514. doi:10.1093/annonc/mdx414

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。